SSR3

Summary

SSR3 (signal sequence receptor subunit 3, HGNC:11325) is a protein-coding gene on chromosome 3q25.31, encoding Translocon-associated protein subunit gamma (Q9UNL2). TRAP proteins are part of a complex whose function is to bind calcium to the ER membrane and thereby regulate the retention of ER resident proteins.

The signal sequence receptor (SSR) is a glycosylated endoplasmic reticulum (ER) membrane receptor associated with protein translocation across the ER membrane. The SSR is comprised of four membrane proteins/subunits: alpha, beta, gamma, and delta. The first two are glycosylated subunits and the latter two are non-glycosylated subunits. This gene encodes the gamma subunit, which is predicted to span the membrane four times.

Source: NCBI Gene 6747 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital disorder of glycosylation (Moderate, GenCC)
• GWAS associations: 6
• Clinical variants (ClinVar): 48 total — 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_007107

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11325
Approved symbol	SSR3
Name	signal sequence receptor subunit 3
Location	3q25.31
Locus type	gene with protein product
Status	Approved
Aliases	TRAPG
Ensembl gene	ENSG00000114850
Ensembl biotype	protein_coding
OMIM	606213
Entrez	6747

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 9 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000265044, ENST00000463503, ENST00000464138, ENST00000467733, ENST00000467789, ENST00000476217, ENST00000478842, ENST00000496050, ENST00000498205, ENST00000896020, ENST00000896021, ENST00000926887, ENST00000960095

RefSeq mRNA: 4 — MANE Select: NM_007107 NM_001308197, NM_001308204, NM_001308205, NM_007107

CCDS: CCDS3176, CCDS77846, CCDS82865

Canonical transcript exons

ENST00000265044 — 5 exons

Exon	Start	End
ENSE00001157057	156539553	156543269
ENSE00001861920	156554957	156555117
ENSE00003550820	156544308	156544439
ENSE00003603284	156553655	156553781
ENSE00003613367	156548905	156549003

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 99.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 286.2892 / max 4564.9179, expressed in 1825 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45257	250.0214	1825
45258	36.2679	1818

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	99.25	gold quality
stromal cell of endometrium	CL:0002255	99.14	gold quality
calcaneal tendon	UBERON:0003701	98.96	gold quality
seminal vesicle	UBERON:0000998	98.28	gold quality
endocervix	UBERON:0000458	98.24	gold quality
colonic epithelium	UBERON:0000397	98.22	gold quality
islet of Langerhans	UBERON:0000006	98.12	gold quality
rectum	UBERON:0001052	98.06	gold quality
caput epididymis	UBERON:0004358	98.03	gold quality
adrenal tissue	UBERON:0018303	98.02	gold quality
corpus epididymis	UBERON:0004359	98.01	gold quality
pancreas	UBERON:0001264	97.92	gold quality
monocyte	CL:0000576	97.84	gold quality
tendon	UBERON:0000043	97.80	gold quality
left uterine tube	UBERON:0001303	97.80	gold quality
endometrium	UBERON:0001295	97.63	gold quality
pylorus	UBERON:0001166	97.60	gold quality
ectocervix	UBERON:0012249	97.54	gold quality
heart right ventricle	UBERON:0002080	97.50	gold quality
heart left ventricle	UBERON:0002084	97.43	gold quality
cardiac ventricle	UBERON:0002082	97.42	gold quality
pericardium	UBERON:0002407	97.42	gold quality
body of uterus	UBERON:0009853	97.29	gold quality
gall bladder	UBERON:0002110	97.28	gold quality
left ovary	UBERON:0002119	97.22	gold quality
mononuclear cell	CL:0000842	97.11	gold quality
right ovary	UBERON:0002118	97.08	gold quality
lower esophagus muscularis layer	UBERON:0035833	97.07	gold quality
lower esophagus	UBERON:0013473	97.06	gold quality
leukocyte	CL:0000738	97.05	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-MTAB-9467	yes	943.19
E-CURD-88	yes	424.66
E-HCAD-1	yes	62.09
E-CURD-46	yes	59.51
E-HCAD-4	yes	57.77
E-CURD-122	yes	53.13
E-MTAB-8410	yes	41.83
E-HCAD-5	yes	33.17
E-HCAD-9	yes	26.09
E-HCAD-11	yes	22.95
E-MTAB-10553	yes	10.77
E-MTAB-10042	yes	6.88
E-MTAB-6075	no	1049.03
E-CURD-114	no	21.85
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT5A, STAT5B

miRNA regulators (miRDB)

170 targeting SSR3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-590-3P	99.96	74.34	6478

Literature-anchored findings (GeneRIF, showing 8)

• translocon-associated protein subunit gamma (TRAPgamma) was identified as a novel TR3 binding partner. (PMID:23660295)
• Data suggest that the mutation leads to complete absence of TRAP gamma (SSR3). (PMID:28218252)
• SSR3 acts as an oncogene in hepatocellular carcinoma with overexpression predicting poor survival. (PMID:29940286)
• Mutations in the translocon-associated protein complex subunit SSR3 cause a novel congenital disorder of glycosylation. (PMID:30945312)
• TRAPgamma-CDG shows asymmetric glycosylation and an effect on processing of proteins required in higher organisms. (PMID:32332102)
• The Role of TRAPgamma/SSR3 in Preproinsulin Translocation Into the Endoplasmic Reticulum. (PMID:34857543)
• Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. (PMID:35552677)
• Signal sequence receptor subunit 3: A novel indicator of immunosuppressive tumor microenvironment and clinical benefits from immunotherapy. (PMID:37652395)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ssr3	ENSDARG00000014165
mus_musculus	Ssr3	ENSMUSG00000027828
rattus_norvegicus	Ssr3	ENSRNOG00000011148
drosophila_melanogaster	CG5885	FBGN0025700
caenorhabditis_elegans		WBGENE00021420

Protein

Protein identifiers

Translocon-associated protein subunit gamma — Q9UNL2 (reviewed: Q9UNL2)

Alternative names: Signal sequence receptor subunit gamma

All UniProt accessions (3): Q9UNL2, C9J365, C9JA28

UniProt curated annotations — full annotation on UniProt →

Function. TRAP proteins are part of a complex whose function is to bind calcium to the ER membrane and thereby regulate the retention of ER resident proteins.

Subunit / interactions. Heterotetramer of TRAP-alpha, TRAP-beta, TRAP-delta and TRAP-gamma.

Subcellular location. Endoplasmic reticulum membrane.

Similarity. Belongs to the TRAP-gamma family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UNL2-1	1	yes
Q9UNL2-2	2

RefSeq proteins (4): NP_001295126, NP_001295133, NP_001295134, NP_009038* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009779	SSR3	Family

Pfam: PF07074

UniProt features (14 total): topological domain 4, modified residue 4, transmembrane region 4, chain 1, splice variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9N9J	ELECTRON MICROSCOPY	3.2
9YGY	ELECTRON MICROSCOPY	4.1
8B6L	ELECTRON MICROSCOPY	7.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UNL2-F1	84.52	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 7, 11, 105, 1

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1799339	SRP-dependent cotranslational protein targeting to membrane
R-HSA-392499	Metabolism of proteins
R-HSA-72766	Translation

MSigDB gene sets: 246 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, WANG_RECURRENT_LIVER_CANCER_UP, GOBP_PROTEIN_TARGETING, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ENDOPLASMIC_RETICULUM, KYNG_DNA_DAMAGE_DN, KYNG_DNA_DAMAGE_BY_4NQO, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, MODULE_503, GOBP_PROTEIN_TARGETING_TO_MEMBRANE, MODULE_195, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, BYSTROEM_CORRELATED_WITH_IL5_DN

GO Biological Process (1): SRP-dependent cotranslational protein targeting to membrane (GO:0006614)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Translation	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
translation	1
cotranslational protein targeting to membrane	1
protein targeting to ER	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1004 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SSR3	SSR1	P43307	998
SSR3	SSR2	P43308	996
SSR3	SSR4	P51571	978
SSR3	SEC61A1	P38378	692
SSR3	DDOST	P39656	591
SSR3	OST4	P0C6T2	565
SSR3	OSTC	Q9NRP0	531
SSR3	RPL31	P12947	525
SSR3	SSTR3	P32745	521
SSR3	STT3A	P46977	511
SSR3	STT3B	Q8TCJ2	504
SSR3	SPCS2	Q15005	496
SSR3	HRH4	Q9H3N8	475
SSR3	SEC63	Q9UGP8	460
SSR3	KRTCAP2	Q8N6L1	443

IntAct

111 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
	DDX3X	psi-mi:“MI:0914”(association)	0.630
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
RABAC1	SSR3	psi-mi:“MI:0915”(physical association)	0.560
RPN1	APBB1	psi-mi:“MI:0914”(association)	0.530
	SCD	psi-mi:“MI:0914”(association)	0.500
SPAG1	SSR3	psi-mi:“MI:0915”(physical association)	0.400
COL6A6	SSR3	psi-mi:“MI:0915”(physical association)	0.400
KLRC4	SSR3	psi-mi:“MI:0915”(physical association)	0.400
RPS8	SSR3	psi-mi:“MI:0915”(physical association)	0.400
CYP2C9	SSR3	psi-mi:“MI:0915”(physical association)	0.400
SSR2	SSR3	psi-mi:“MI:0915”(physical association)	0.400
SERPINB8	SSR3	psi-mi:“MI:0915”(physical association)	0.400
ATF7IP2	SSR3	psi-mi:“MI:0915”(physical association)	0.400
FAM120A	SSR3	psi-mi:“MI:0915”(physical association)	0.400
GRIK3	SSR3	psi-mi:“MI:0915”(physical association)	0.400
SLC22A14	SSR3	psi-mi:“MI:0915”(physical association)	0.400
NDNF	SSR3	psi-mi:“MI:0915”(physical association)	0.400
E2F3	SSR3	psi-mi:“MI:0915”(physical association)	0.400
MEP1B	SSR3	psi-mi:“MI:0915”(physical association)	0.370
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
	ESYT2	psi-mi:“MI:0914”(association)	0.350
E5	ESYT2	psi-mi:“MI:0914”(association)	0.350
	HAX1	psi-mi:“MI:0914”(association)	0.350

BioGRID (204): CLTC (Co-fractionation), DDX39A (Co-fractionation), DDX39B (Co-fractionation), HSD17B12 (Co-fractionation), MAGT1 (Co-fractionation), RPL10A (Co-fractionation), RPLP2 (Co-fractionation), RTN4 (Co-fractionation), SEC61A1 (Co-fractionation), SSR1 (Co-fractionation), SSR3 (Co-fractionation), SSR3 (Co-fractionation), SSR3 (Co-fractionation), SSR3 (Co-fractionation), SSR3 (Co-fractionation)

ESM2 similar proteins: A1CJW1, A1D7K7, A3LU53, A4R0J5, A5DGY3, A6R3V7, A6ZV87, A7F5K4, A7TSA7, A9JTJ0, B2WDD8, B3LIC1, B4UN04, B8JLV7, O64614, P0CS24, P41806, Q08013, Q0CXF5, Q0UV26, Q28CH8, Q28GR4, Q2HDV5, Q3B8G4, Q3SZ87, Q3UDR8, Q42337, Q4V7U1, Q4V8S3, Q5BK13, Q5F384, Q5RAS8, Q5RCD7, Q5SYH2, Q5ZLL0, Q6BXM0, Q6CDK3, Q6CQP9, Q6TUD4, Q75EI3

Diamond homologs: Q08013, Q3SZ87, Q55GT5, Q5RCD7, Q9DCF9, Q9UNL2

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SSR3	“form complex”	“TRAP complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 116 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of CDH1 posttranslational processing and trafficking to plasma membrane	5	21.3×	2e-04
Maturation of spike protein	6	20.2×	5e-05
SRP-dependent cotranslational protein targeting to membrane	14	17.8×	2e-11
Regulation of RAS by GAPs	6	14.7×	2e-04
Maturation of DENV proteins	5	13.4×	1e-03
Translation	12	9.4×	1e-06
Anchoring of the basal body to the plasma membrane	6	8.6×	1e-03
ER-Phagosome pathway	5	8.2×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	8	14.7×	5e-05
positive regulation of apoptotic process	10	5.6×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	22
Likely benign	13
Benign	6

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
982233	NM_007107.5(SSR3):c.278_281del (p.Glu93fs)	Likely pathogenic

SpliceAI

989 predictions. Top by Δscore:

Variant	Effect	Δscore
3:156544307:CA:C	donor_gain	1.0000
3:156544435:AGATT:A	acceptor_gain	1.0000
3:156544436:GATT:G	acceptor_gain	1.0000
3:156544437:ATT:A	acceptor_gain	1.0000
3:156544438:TT:T	acceptor_gain	1.0000
3:156544439:TCT:T	acceptor_loss	1.0000
3:156544440:C:CC	acceptor_gain	1.0000
3:156548867:C:CA	donor_gain	1.0000
3:156548885:A:AC	donor_gain	1.0000
3:156548886:C:CC	donor_gain	1.0000
3:156548888:TTAA:T	donor_gain	1.0000
3:156548999:CTACT:C	acceptor_gain	1.0000
3:156549000:TACT:T	acceptor_gain	1.0000
3:156549002:CT:C	acceptor_gain	1.0000
3:156549004:C:CC	acceptor_gain	1.0000
3:156553653:A:AC	donor_gain	1.0000
3:156553654:C:CC	donor_gain	1.0000
3:156554952:CTCA:C	donor_loss	1.0000
3:156554953:TCA:T	donor_loss	1.0000
3:156554955:A:AC	donor_gain	1.0000
3:156554956:C:CA	donor_gain	1.0000
3:156554956:CA:C	donor_gain	1.0000
3:156554956:CAG:C	donor_gain	1.0000
3:156554956:CAGA:C	donor_gain	1.0000
3:156554956:CAGAT:C	donor_gain	1.0000
3:156544302:GGAT:G	donor_loss	0.9900
3:156544303:GAT:G	donor_loss	0.9900
3:156544304:ATAC:A	donor_loss	0.9900
3:156544305:T:TG	donor_loss	0.9900
3:156544306:A:AC	donor_gain	0.9900

AlphaMissense

1214 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:156543238:C:G	G175R	1.000
3:156543238:C:T	G175R	1.000
3:156544402:C:G	A133P	1.000
3:156544413:G:T	A129D	1.000
3:156544414:C:G	A129P	1.000
3:156548977:A:T	V96D	1.000
3:156555030:G:C	F20L	1.000
3:156555030:G:T	F20L	1.000
3:156555032:A:G	F20L	1.000
3:156543237:C:T	G175E	0.999
3:156544373:G:C	N142K	0.999
3:156544373:G:T	N142K	0.999
3:156544401:G:T	A133D	0.999
3:156544403:T:A	E132D	0.999
3:156544403:T:G	E132D	0.999
3:156544439:T:A	R120S	0.999
3:156544439:T:G	R120S	0.999
3:156548913:T:A	K117N	0.999
3:156548913:T:G	K117N	0.999
3:156548988:C:A	R92S	0.999
3:156548988:C:G	R92S	0.999
3:156553660:C:A	K85N	0.999
3:156553660:C:G	K85N	0.999
3:156553662:T:C	K85E	0.999
3:156553664:A:G	L84P	0.999
3:156553669:A:C	F82L	0.999
3:156553669:A:T	F82L	0.999
3:156553671:A:G	F82L	0.999
3:156553688:G:T	A76E	0.999
3:156553708:G:C	S69R	0.999

dbSNP variants (sampled 300 via entrez): RS1000170005 (3:156545606 G>A), RS1000201899 (3:156556720 G>A), RS1000254328 (3:156556912 C>T), RS1000389941 (3:156544507 G>T), RS1000457369 (3:156550969 G>A), RS1000639588 (3:156550738 T>C), RS1000660182 (3:156553405 A>G), RS1000739567 (3:156546075 A>G), RS1000753763 (3:156552130 A>G), RS1000770356 (3:156547169 TTA>T,TTATA), RS1000850496 (3:156539498 T>C), RS1000958757 (3:156546393 G>A), RS1000971300 (3:156547529 C>A,T), RS1001239392 (3:156541144 G>A), RS1001304017 (3:156539747 C>T)

Disease associations

OMIM: gene MIM:606213 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital disorder of glycosylation	Moderate	Autosomal recessive

Mondo (1): congenital disorder of glycosylation (MONDO:0015286)

Orphanet (1): Congenital disorder of glycosylation (Orphanet:137)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST004713_16	Testicular germ cell tumor	7.000000e-09
GCST007576_384	Chronotype	6.000000e-08
GCST007799_13	Asthma (adult onset)	4.000000e-06
GCST009391_117	Metabolite levels	5.000000e-06
GCST010725_61	Malaria	1.000000e-06
GCST010725_81	Malaria	6.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0008328	chronotype measurement
EFO:1002011	adult onset asthma
EFO:0010354	diacylglycerol 36:1 measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018981	Congenital Disorders of Glycosylation	C16.320.565.202.125; C18.452.648.202.125

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067174 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 4 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.30	Kd	50.5	nM	CHEMBL5653589
7.30	ED50	50.5	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149499: Binding affinity to human SSR3 incubated for 45 mins by Kinobead based pull down assay	kd	0.0505	uM

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, affects methylation, decreases expression, affects cotreatment	5
Cyclosporine	increases expression	4
Valproic Acid	affects expression, increases expression	3
bisphenol A	affects expression, increases expression	2
cobaltous chloride	decreases expression	2
FR900359	decreases phosphorylation	1
bisphenol F	increases expression	1
methylmercuric chloride	increases expression	1
lead acetate	increases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
ochratoxin A	affects cotreatment, decreases expression	1
cupric chloride	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
torcetrapib	increases expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
jinfukang	decreases expression	1
bisphenol AF	increases expression	1
Temozolomide	decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Aspirin	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1
Citrinin	affects cotreatment, decreases expression	1
Clozapine	decreases expression	1
Diuron	decreases expression	1
Doxorubicin	affects expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652541	Binding	Binding affinity to human SSR3 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

9 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT07572825	PHASE1	NOT_YET_RECRUITING	Assessing the Safety and Tolerability of NMN in DHDDS-CDG
NCT02089789	Not specified	RECRUITING	Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
NCT02503267	Not specified	UNKNOWN	Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects
NCT02955264	Not specified	COMPLETED	Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation
NCT03250728	Not specified	COMPLETED	Role of the Endothelium in Stroke-like Episode Among CDG Patients
NCT03560570	Not specified	COMPLETED	Study of Hemostasis in Patients With Congenital Disorder of Glycosylation
NCT04198987	Not specified	COMPLETED	Dietary Monosaccharide Supplementation in Patients With Congenital Disorders of Glycosylation
NCT04199000	Not specified	RECRUITING	Clinical and Basic Investigations Into Congenital Disorders of Glycosylation
NCT04201067	Not specified	COMPLETED	Large-Scale Metabolomic Profiling for the Diagnosis of Inborn Errors of Metabolism